March 2, 2022
JCR Pharmaceuticals is handing over the Japanese marketing and distribution rights for its Fabrazyme (agalsidase beta) biosimilar to Sumitomo Dainippon Pharma, with a stepwise transfer of the Fabry disease drug slated to begin next month. JCR has been selling the...read more